Paraprotein-related renal disease and amyloid

[1]  M. Dimopoulos,et al.  Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.

[2]  M. Skinner,et al.  XIth International Symposium on Amyloidosis , 2007 .

[3]  Neil D Evans,et al.  Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. , 2006, Journal of the American Society of Nephrology : JASN.

[4]  A. Dispenzieri,et al.  Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[5]  M. Haubitz,et al.  Myeloma--new approaches to combined nephrological-haematological management. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  Amit X Garg,et al.  Plasma Exchange When Myeloma Presents as Acute Renal Failure , 2005, Annals of Internal Medicine.

[7]  A. Dispenzieri,et al.  Amyloidosis: diagnosis and management. , 2005, Clinical lymphoma & myeloma.

[8]  F. Locatelli,et al.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  M. Pepys,et al.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.

[10]  V. D’Agati,et al.  Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. , 2003, Kidney international.

[11]  J. Goujon,et al.  Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. , 2002, Kidney international.

[12]  L. Knudsen,et al.  Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.

[13]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[14]  C. Winearls,et al.  Acute myeloma kidney. , 1995, Kidney international.

[15]  A. Solomon,et al.  Nephrotoxic potential of Bence Jones proteins. , 1991, The New England journal of medicine.